Patent intelligence · US
US 10117937
Highly branched alpha-D-glucans
Highly branched alpha-D-glucans
Patent details — US 10117937
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 6, 2018
- Expiration
- Nov 1, 2038
- Applicant
- Phytoption LLC
- Claims
- 19
- CPC classes
- A61K, A61K2800/49, A61K2800/544, A61K31/192
Quick answer
US 10117937 (Highly branched alpha-D-glucans) is held by Phytoption LLC. Status: granted. Granted Nov 6, 2018. Expires Nov 1, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Phytoption LLC
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K2800/49, A61K2800/544, A61K31/192, A61K31/343, A61K47/36
More from Phytoption LLC
Related pharmaceutical patents in our USPTO index.
-
US 11596610
Compositions in support of health and mental accuity
granted -
US 9289513
Targeted cytokine for treatment of musculoskeletal diseases
granted -
US 8685932
Targeted transforming growth factor-beta-bound IgG for Treatment of Diseases
granted -
US 6770283
DNA expression systems based on alphaviruses
expired -
US 6692750
Alphavirus expression vector
expired -
US 6566093
Alphavirus cDNA vectors
expired -
US 6224879
Alphavirus expression vector
expired
Frequently asked questions
What is US patent 10117937?
US 10117937 (Highly branched alpha-D-glucans) is held by Phytoption LLC. Status: granted. Granted Nov 6, 2018. Expires Nov 1, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10117937?
Phytoption LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 10117937 expire?
Our index shows an expiration date of Nov 1, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.